In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.

During a tense hearing before a Senate committee on Tuesday, Novo Nordisk CEO Lars Fruergaard Jørgensen faced toug

Novo Nordisk's stock market performance has been incredible in recent years. It's hard to find a better growth stock among similarly sized drugmakers. However, it isn't a particularly good d ividend stock.

The healthcare company's pivot into a new set of technologies will have many implications for the stock.